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ABSTRACT
Glioblastoma multiforme (GBM) is the most malignant subtype of brain cancer. However, current clinical treatments 
for GBM are limited in effectiveness and often impose additional side effects on patients. Here, we developed targeted 
anti-cancer therapy (TAT) using neural stem cells (NSC) as delivery agent to transport anti-cancer compounds directly to 
GBM in vitro. Anti-cancer active compounds: Tannic acid (TA) and gallic acid (GA) were extracted from local medicinal 
plant - Quercus infectoria (QI) using soxhlet technique with 100% methanol (QI-100%) or 70% methanol (QI-70%) 
solvent. Concentration of TA and GA measured using HPLC were 72.56 and 43.66 μg/mL in QI-100%, while in QI-70%, 
the concentrations were 72.41 and 43.31 μg/mL, respectively. Cytotoxicity effects of QI-100% and QI-70% on human 
GBM cell line (DBTRG-05MG), human NSC line (H9-hNSC) and human normal brain glial cell line (SVG-p12) (as negative 
control) were determined using MTT assay. Both QI-100% and QI-70% showed anti-proliferative properties against 
DBTRG-05MG at IC50, but not on H9-hNSC and SVG-p12. Taken together, data indicated that both QI extracts contained 
TA and GA which exhibit anti-proliferative effect specifically on cancerous cells only. Next, QI-treated H9-hNSC was 
seeded in a modified Boyden chamber for 12 h to investigate its migration capacity towards DBTRG-05MG. The result 
showed that H9-hNSC migrated towards DBTRG-05MG with 4-folds higher capacity compared to control. In addition, 
the migration of QI-100% treated H9-hNSC successfully reduced the number of DBTRG-05MG, indicating the anti-GBM 
potential of these cells after migration. In conclusion, NSC could be a specific anti-cancer compound delivery agent for 
GBM, reducing unwanted side effects on patients. 
Keywords: Glioblastoma multiforme (GBM); neural stem cells (NSC); Quercus infectoria (QI); targeted anti-cancer 
therapy (TAT)
ABSTRAK
Glioblastoma multiforme (GBM) adalah sub-jenis kanser otak yang paling berbahaya. Rawatan klinikal pada masa kini 
adalah terhad daripada segi keberkesanan serta boleh mengakibatkan kesan sampingan pada pesakit. Kajian ini meneliti 
rawatan bersasarkan kanser (TAT) dengan menggunakan sel stem  neuron (NSC) sebagai pembawa sebatian anti-kanser 
ke sel sasaran GBM. Sebatian anti-kanser: Asid tanik (TA) dan asid galik (GA) diekstrak daripada tumbuhan perubatan 
tempatan - Quercus infectoria (QI) dengan menggunakan 100% (QI-100%) dan 70% (QI-70%) metanol melalui teknik 
soxhlet. Kepekatan TA dan GA hasilan ujian HPLC adalah 72.56 dan 43.66 μg/mL dalam QI-100%, manakala dalam 
QI-70% adalah 72.41 dan 43.31 μg/mL. Kesan sitotoksisiti QI-100% dan QI-70% terhadap sel GBM manusia (DBTRG-
05MG), sel NSC manusia (H9-hNSC) dan sel glial otak manusia (SVG-p12) dikaji dengan asai MTT. Kedua-dua QI-100% 
dan QI-70% menunjukkan perencatan populasi sel DBTRG-05MG pada IC50, tetapi tidak merencatkan populasi sel H9-
hNSC dan SVG-p12. Data terkumpul menunjukkan bahawa estrak QI mengandungi sebatian TA dan GA yang mempunyai 
aktiviti perencatan spesifik terhadap sel kanser sahaja. Seterusnya, H9-hNSC yang telah dirawat dengan QI dimasukkan 
dalam kebuk Boyden terubah suai selam 12 jam untuk tujuan kajian kapasiti migrasi H9-hNSC ke DBTRG-05MG. Data 
menunjukkan kapasiti migrasi H9-hNSC ke DBTRG-05MG adalah 4 kali ganda lebih tinggi daripada sampel kawalan. 
Selain itu, migrasi H9-hNSC yang telah dirawat dengan QI-100% berupaya untuk mengurangkan bilangan sel-sel DBTRG-
05MG. Ini membuktikan potensi anti-GBM sel berkenaan selepas migrasi. Kesimpulannya, NSC boleh digunakan sebagai 
agen pembawa sebatian anti-kanser dalam rawatan GBM untuk mengurangkan kesan sampingan terhadap pesakit.
Kata kunci: Glioblastoma multiforme (GBM); Quercus infectoria (QI); rawatan bersasarkan kanser (TAT); sel stem neuron 
(NSC)
INTRODUCTION
Glioma is a general term used to describe any brain 
primary tumor that derived from supportive nerve cells 
known as glial cells. The main functions of glial cells 
are to provide protection, nutrients, oxygen, as well as 
insulation for the neuronal cells. The occurrence of glioma 
1210 
can therefore affect the neurons and consequently damage 
the brain. Glioblastoma Multiforme (GBM) is the most 
common and malignant subtype of brain tumor (Ramirez 
et al. 2013). Due to its high degree of malignancy and 
devastating outcome, GBM is always the top concern in 
various ongoing scientific researches or clinical trials 
related to brain cancer, so as in this study. At present, the 
standard treatment for GBM relies on the effectiveness of 
surgery and chemo-radiation therapy (Zhang et al. 2012). 
During surgery, neurosurgeons perform maximal surgical 
resection of the GBM tumor within safe margins depending 
on its location. This is to remove as much tumor tissue 
as possible. Following surgical procedure, the patient 
undergoes radiotherapy over a period of weeks. The aim 
is to kill the remaining tumor using high energy beams. 
As a follow-up, chemotherapy usually is employed. It is 
reported that patients who received adjuvant chemotherapy 
with radiotherapy for GBM show greater survival than those 
who received radiotherapy treatment alone, indicating 
the importance of chemotherapy to treat GBM (Zhang et 
al. 2012). 
 Nonetheless, current chemotherapy treatment 
regimens are unable to target specifically to GBM tumor 
tissue partly due to the traditional drug administration 
route via systemic circulation system which delivers the 
drug all over body (Ramirez et al. 2013). These drugs 
indiscriminately kill both normal and cancerous cells, 
causing unavoidable side effects on the healthy normal 
cells. These side effects will not only place extra burden on 
the patients, but also reduce compliance to the treatment. 
As a consequence, the tumor cannot be completely healed, 
leading to possible recurrence. Thus, in order to prevent 
this problem, an alternative chemotherapy targeting 
glioma specifically to reduce unwanted side effects and 
increase cancerous cell killing efficiency is necessary. 
 Recently, targeted anti-cancer therapy (TAT) is gaining 
a lot of attention worldwide as one of the reliable solution 
for this issue. Similar to conventional chemotherapy, TAT 
uses drugs with anti-cancer properties, but instead of inject 
the drugs systemically, the drugs are packaged in special 
delivery vehicles which transport the drugs directly to the 
cancer cells at tumor site. Hence, the TAT only targets the 
cancer cells and causes less damage to healthy cells. As 
a result, the patients will not suffer much adverse effects 
compared to the current chemotherapy. There are several 
important criteria for the selection of TAT delivery agent; 
first, the inert reactivity of the agent to the anti-cancer 
drug; second, the ability of the agent to migrate to the 
cancer site specifically and third, the ability of the agent 
to penetrate an intact and functional brain-tumour-cell 
barrier throughout the entire brain (Argarwal et al. 2011). 
Here, we aimed to investigate the potential of neural stem 
cells (NSCs) as delivery agent for TAT in treating GBM. 
 NSCs are stem cells found abundantly in both brain 
and central nervous system. They have the ability to 
self-replicate and to differentiate into specialized cells 
such as neurons, astrocytes and oligodendrocytes when 
stimulated (Kornblum 2007). NSCs in adult brain possess 
unique potential to migrate towards pathologically altered 
tissue locations in primary brain tumor (Aboody et al. 
2000). Genetically modified NSCs also proved to deliver 
therapeutic proteins such as interleukins to tumor sites 
(Benedetti et al. 2000). However, to date, there is no study 
to determine NSC’s capacity to migrate to GBM cells in vitro 
carrying an anti-GBM active compound isolated from the 
galls of a local natural medicinal plant known as Quercus 
infectoria (QI). QI galls are found on twigs of dyer’s oak 
tree, a tree which can grow from 4 to 6 feet tall (Shrestha et 
al. 2014). These galls are formed due to enzyme stimulation 
from larva of gall wasp. QI galls contain 50% to 70% 
of tannic acid (TA) constituents followed by gallic acid 
(GA) and other minor elements such as syringic acid and 
ellagic acid (Shaikh et al. 2013). TA and GA are the major 
constituents of QI that have anti-proliferative activities 
against cancer cells. In previous study, TA and GA extracted 
from QI were found to have anti-proliferative properties 
against cervical cancer cells (HeLa) and ovarian cancer 
cells (Caov-3) (Hasmah et al. 2010). This is the first study 
to investigate cytotoxivity effect of QI extract on GBM and 
the capacity of NSCs to deliver this potential anti-GBM 
extract to human GBM cell line in vitro.
MATERIALS AND METHODS
CELL CULTURE
Cancerous human GBM cell line (DBTRG-05MG) cells were 
cultured in a T25 tissue culture flask filled with 2 mL of 
complete media composed of Roswell Park Memorial 
Institute (RPMI) media supplemented with 10% heat 
inactivated fetal bovine serum (FBS) and 1% penicillin-
streptomycin antibiotics (pen-strep) at cell density of 1 
× 105 cells/flask. On the other hand, human neural stem 
cell line (H9-hNSC) were cultured in a T25 tissue culture 
flask filled with complete media composed of StemPro 
NSC Serum free media supplemented with KnockOut 
DMEM/F-12, 1.0% GlutaMAX-I supplement, 0.02% basic 
fibroblast growth factor (bFGF), 0.02% Epidermal growth 
factor (EGF) and 2.0% StemPro Neural Supplement at 
cell density of 1 × 105 cells/flask. The flasks used to 
culture H9-hNSC cells were pre-coated with CELLStart 
and incubated an hour at 37ºC before transferring H9-
hNSC cells. Normal human glial cell line (SVG-p12) was 
also used in this study as negative control. This cell was 
cultured in Eagle’s Minimum Essential Medium (EMEM) 
complete culture media supplemented with FBS and 1% 
pen-strep at cell density of 1 × 105 cells/flask. All the cell 
culture flasks were incubated in humidified incubator with 
5% CO2 at 37°C for 24 h. Used media was replaced with 
2 mL fresh complete media every two days and cultured 
until confluency.
PLANT EXTRACTION
QI gall powder was prepared as described in previous 
study (Baharuddin et al. 2015). 15 g of the QI powder 
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was transferred into thimble added with 450 mL of 100% 
methanol (QI-100%) or 70% methanol (QI-70%) solvent. 
The temperature of the extraction was set at the boiling 
point of methanol (64.7°C) and the extraction was carried 
out for 6 h. The methanol from the extract was removed 
using rotary evaporator at 40°C until the extract completely 
dried. The yield of both QI-100% and QI-70% were 
calculated using the following equation:
 Percentage of yield   Final weight (g)   × 100%
 extraction (%) = ––––––––––––––
   Initial weight (g)
DETERMINATION OF PHENOLIC COMPOUNDS IN QI 
METHANOL EXTRACTS
Concentration of phenolic compounds in QI-100% and 
QI-70% were determined using high performance liquid 
chromatography (HPLC) with TA and GA as standard 
markers. The flow rate of mobile phase was 1.0 mL/min 
and the detection wavelength was 280 nm. For TA HPLC 
assay, Poroshell 120 EC-18 (4.6 × 50 mm) was used as 
stationary phase while methanol (solvent A) and 1% of 
acetic acid (solvent B) were used as gradient system. The 
gradient system for TA HPLC assay started with 60% solvent 
A, followed by 35% solvent A and 10% solvent A. Then, 
the gradient ended with 60% of solvent A. Whereas for GA 
HPLC assay, Zorbax Eclipse Plus C18 (4.6 × 150 mm) was 
used as stationary phase while methanol (solvent A) and 
4% acetic acid (solvent B) were used as gradient system. 
The gradient system for GA HPLC assay started with 100% 
solvent B, followed by 50% solvent B and 20% solvent 
B. The gradient ended with 100% solvent B. The peaks 
of the extracts were identified by comparing them with 
peaks of the standard markers. The percentage of TA and 
GA were calculated based on the area under curve (AUC) 
of QI sample chromatogram, compared to AUC of standard 
chromatogram. The concentration of the TA and GA of each 
extracts was calculated using equation below:
Sample Area under curve of sample  Standard
concentration: ––––––––––––––––––––––– × concentration Area under curve of standard 
ANTI-OXIDANT ASSAY
DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging 
activity assay was performed with minor modification of 
previous study (Syukriah et al. 2014). First, 1 mg/mL QI-
100% and QI-70% solutions were prepared by dissolving 10 
mg of QI-100% and QI-70% extract in 10 mL of methanol, 
respectively. Then, 2.5 mL of the extract solutions were 
added to 2.5 mL of 0.08 mg/mL DPPH solution. The tubes 
were left in dark for 30 min at room temperature. Blank 
(control) contained only the methanol was also prepared 
for DPPH assay. The optical density (OD) of each sample 
was measured using spectrophotometer at wavelength 517 
nm. Triplicates were measured for each sample and average 
was calculated. Percentage of DPPH radical scavenging was 
calculated as follows:
 Percentage of  Absorbance control –  radical scavenging = Absorbance sample × 100%     –––––––––––––––––          Absorbance control 
ANTI-PROLIFERATIVE ASSAY
DBTRG-05MG, H9-hNSCs and SVG-p12 cells were 
seeded into 96-well plate at density 5 × 104 cells per 
well, respectively. Complete media with gradients 
concentrations (0, 25, 50, 75 and 100 μg/mL) of QI plants 
extracts (QI-100% and QI-70%) and synthetic drugs 
(tamoxifen and temozolomide; used as positive controls) 
were added into respective wells with seeded cells. The 
plate was incubated at 37°C for 72 h. Then, MTT solution 
(5 mg/mL) was added into each of the wells. The plates 
were incubated in humidified incubator with at 37°C for 
4 h. Absolute DMSO was added into the wells and OD 
was measured at wavelength 570 nm. The half maximal 
inhibitory concentration (IC50) of each solvent was determined using graph percentage of viable cells against 
concentration (μg/mL). The percentage of viable cells was 
calculated using formula as follows:
 Percentage of      Absorbance in a well viable cells (%) =  ––––––––––––––––––––––––––  × 100%       Absorbance of negative control  
COLORIMETRIC CELL MIGRATION ASSAY
Milipore Colorimetric Cell Migration Assay (Boyden 
Chamber Assay) was used to investigate cell migration. 
The assay composed of a 24-well plate (bottom chamber) 
and 24 pieces of insert with polycarbonate membrane of 8 
μm pore size (upper chamber). First, the 24-well plate was 
seeded with 1 × 105 DBTRG-05MG cells/well and cultured 
in humidified incubator with 5% CO2 at 37°C for 24 h. Then, used media was aspirated and the cells were washed 
with 1 mL sterile PBS to ensure no presence of serum in the 
wells. The cells were starved by adding 500 μL of serum 
free RPMI media per well and the plate was incubated in 
humidified incubator with 5% CO2 at 37°C prior to the cell migration assay. At the same time, H9-hNSCs were 
treated for 24 h with optimum concentrations of QI plants 
extracts and synthetic drugs as determined from the 
previous anti-proliferation assay. After that, the treated 
H9-hNSC cells were harvested and seeded onto the inserts 
with polycarbonate membrane at cell density of 7.5 × 104 
cells/insert. Negative control insert contained the untreated 
H9-hNSC and blank insert contained only the serum free 
medium was also prepared for the assay. All the inserts 
prepared were transferred to the 24-well plate pre-seeded 
with DBTRG-05MG using sterile forceps. Then the whole 
plate was incubated in humidified incubator with 5% CO2 at 37°C for 12 h. After 12 h, the used RPMI media from 
the interior of the inserts were removed carefully and cells 
that have migrated to the bottom of the insert membrane 
were stained based on manufacturer’s protocol. While 
the DBTRG-05MG at the bottom wells of the 24-well plate 
were subjected to MTT assay to measure cell viability after 
migration assay. 
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STATISTICAL ANALYSIS
Data obtained were analysed using SPSS 22.0 for windows. 
All data were obtained from at least three independent 
experiments and the analyses of these data were expressed 
as average value ± standard deviation (SD). The statistical 
differences of measurements made in same cell type 
but different treatments were analysed using a paired 
T-test, whereas multiple comparisons between different 
treatments on different cell types were analysed using 
one-way analysis of variance (ANOVA). A value of p < 0.05 
was considered statistically significant.
TABLE 1. Total extraction yield and total plant extract 
of QI methanol extracts
Type of solvent Plant extract yield 
(g)
Yield 
(%)
QI-100%
QI-70%
2.95
2.89
19.7
19.3
TABLE 2. DPPH free radical scavenging activity 
of QI methanol extracts
Type of solvent DPPH free radicals scavenging 
(%)
QI-100%
QI-70%
97.3 ± 1.4
96.4 ± 3.7
RESULTS
PLANT EXTRACTION YIELD AND ANTIOXIDANT ASSAY
Both QI-100% and QI-70% generated approximately 20% 
extraction yield using methanol soxhlet technique. There 
was no significant different in yield percentage between 
QI-100% and QI-70%, indicating the concentration of 
methanol solvent did not affect the extraction yield (Table 
1). Similarly, free radical scavenging activity was exhibited 
similarly high in both QI-100% (97.3 ± 1.4%) and QI-70% 
(96.4 ± 3.7%) (Table 2). 
FIGURE 1. HPLC chromatogram of tannic acid (TA) in (A) Q. infectoria 100% methanol extract (QI-100%); (B) Q. infectoria 100% 
methanol extract (QI-70%) and (C) TA standard solutions. The clear peak at retention time ~ 1.5 min indicated the presence of TA
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TABLE 3. Percentage and concentration of TA extracted from QI methanol extracts
Type of solvent Area under curve 
(AUC)
Percentage of TA 
(%)
Concentration of TA 
(μg/mL)
QI-100%
QI-70%
1586.21
1582.73
1.316
1.312
72.56
72.41
HPLC ANALYSIS
Presence of TA in plant extract was indicated by a clear 
single peak that was observed at retention time 0.6 min 
in both HPLC chromatogram of QI-100% (Figure 1(A)) 
and QI-70% (Figure 1(B)). Table 3 shows a slim different 
in percentage and concentration of TA between QI-100% 
(1.316%; 72.56 μg/mL) and QI-70% (1.321%; 72.41 
μg/mL). For GA analysis, a clear peak was observed at 
retention time 1.5 min in both HPLC chromatogram of QI-
100% (Figure 2(A)) and QI-70% (Figure 2(B)), indicating 
the presence of GA in these extracts. The percentage and 
concentration of GA did not differ significantly between 
QI-100% (0.954%; 43.66 μg/mL) and QI-70% (0.949%; 
43.31 μg/mL) as listed in Table 4. 
ANTI-PROLIFERATIVE ASSAY
The IC50 for DBTRG-05MG treated with QI plants extracts (QI-100% and QI-70%) and synthetic drugs (tamoxiden 
and temozolomide) were obtained from MTT assay (Figure 
3(A)). The data showed that Tamoxifen has the highest anti-
proliferative activities (IC50 value = 9 μg/mL) followed by 
QI-100% (IC50 value = 23 μg/mL), QI-70% (IC50 value = 
FIGURE 2. HPLC chromatogram of gallic acid (GA) in (A) Q. infectoria 100% methanol extract (QI-100%); (B) Q. infectoria 100% 
methanol extract (QI-70%) and (C) standard GA solutions. The clear peak at retention time ~ 1.5 min indicated the presence of GA
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34 μg/mL) and temozolomide (IC50 value > 100 μg/mL). 
Similar trend was found for the other two cell lines: H9-
hNSCs and SVG-p12 in which tamoxifen has showed the 
highest anti-proliferative activities followed by QI-100%, 
QI-70 and temozolomide (Figure 3(B) and 3(C)). The IC50 
value of each the treatments were tabulated in Table 5.
 In the comparison between QI methanol extract 
treatments on cancerous brain cells DBTRG-05MG, QI-100% 
had smaller IC50 value compared to QI-70% (Table 5; 
p<0.05). This indicated that the QI-100% extract possibly 
has higher potent to inhibit glioma growth compared to 
QI-70%. On the other hand, in the comparison between 
TABLE 4. Percentage and concentration of GA extracted from QI methanol extracts
Type of solvent Area under curve 
(AUC)
Percentage of GA 
(%)
Concentration of GA 
(μg/mL)
QI-100%
QI-70%
1207.18
1197.64
0.954
0.949
43.66
43.31
FIGURE 3. Gradient concentrations of QI methanol extracts (QI-100% and QI-70%) and synthetic drugs 
(Tamoxifen and Temozolomide) against percentage of viable (A) DBTRG-05MG cells, (B) H9-hNSC cells and 
(C) SVG-p12 cells (negative control). Each point is average percentage of viable cells (comparison to negative 
control, DMSO 1%) with standard deviation of three independent experiments
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QI methanol extract treatments on normal brain stem cell 
H9-hNSCs and brain glial cell SVG-p12 (as control), both 
QI-100% and QI-70% showed higher IC50 value (Table 
5; p<0.05) compared to cancerous DBTRG-05MG cells, 
indicating that these extracts were not cytotoxic to the 
normal cells at a concentration that was cytotoxic to 
cancerous cells. Taken together, the data indicated that the 
inhibitory effect of both QI-100% and QI-70% was more 
potent to cancerous GBM cell line, but less or minimal on 
normal brain cell lines. These result also illustrated the 
suitability of NSC as delivery agent for QI-100% and QI-70% 
due to its low or negative reactivity to these plant extracts 
at a concentrations that could significantly kill the target 
cancerous GBM cells.
 Notably, we found that clinically used anti-cancer 
drug, tamoxifen, showed IC50 at 30 and 16 µg/mL to brain 
stem cells and glial cells, respectively (Figure 3(B), 3(C); 
Table 5). This explained why chemotherapy using clinical 
anti-cancer drug could cause detrimental side effects on 
healthy normal cells. On the other hand, another clinical 
anti-cancer drug, temozolomide, showed IC50 value more 
than 100 µg/mL for DBTRG-05MG, indicating the minimal 
inhibitory effect of this drug on glioma cell line even at high 
concentration. These results suggested that a re-evaluation 
of temozolomide for clinical use is necessary. 
CELL MIGRATION ASSAY
H9-NSCs showed migration from inferior of the insert into 
membrane towards DBTRG-05MG cells seeded in the lower 
chamber after 12 h incubation on a Boyden migration 
chamber (Figure 4(A)). There was no H9-hNSCs observed 
migrated to the lower chamber without DBTRG-05MG 
(empty lower chamber; negative control) (Figure 4(B)), 
indicating that the migration of H9-NSCs is specific in 
direction driven by the cell instinct tropism towards DBTRG-
05MG. This also indicated that the cell migration was not 
due to gravity attraction. However, incubation more than 
12 h on a Boyden migration chamber induced excess cell 
migration in which all cells were eventually attracted to the 
bottom chamber triggered by gravity force (data not shown). 
Therefore, the amount of migrated cells were harvested and 
counted after 12 h incubation period. It was found that the 
migration capacity for H9-hNSC was significantly higher 
TABLE 5. IC50 of QI-100%, QI-70%, tamoxifen and temozolomide on DBTRG-05MG, H9-hNSCs and SVG-p12 
and the optimum concentrations selected for cell migration assay
Treatment IC50 for DBTRG-
05MG (μg/mL)
IC50 for H9-hNSC 
(μg/mL)
IC50 for SVG-p12 
(μg/mL)
Optimum concentration used 
in migration assay $
Tamoxifen 9 30 16.2 10.0
QI-100% 23* 78** >100*** 25.0
QI-70% 34* >100** >100*** 35.0
Temozolomide >100* >100**  >100*** Excluded from migration study due to 
insensitivity to all cell lines
* p < 0.05 vs. Tamoxifen IC50 for DBTRG-05MG 
** p < 0.05 vs. Tamoxifen IC50 for H9-hNSC 
*** p < 0.05 vs. Tamoxifen IC50 for SVG-p12 
# p < 0.05 between the two groups linked with arrow
$ Optimum concentrations for cell migration assay were selected based on a value that is cytotoxic (more than IC50) to DBTRG-05MG but minimal (less than IC50) to other 
cell lines
# #
FIGURE 4. Cell migration assay of (A) H9-hNSC with DBTRG-
05MG seeded at lower chamber (B) H9-hNSC without DBTRG-
05MG seeded at lower chamber (negative control) and (C) blank 
(without both H9-hNSC and DBTRG-05MG). Migrated H9-hNSC 
is indicated by black arrows. Red arrows indicate 8 μm-sized 
pores of polycarbonate membrane of the insert. Magnification: 
40X. (D) Quantification of migrated H9-hNSC. H9-hNSCs 
showed significant increase in migration capacity towards 
DBTRG-05MG. *p<0.05 vs. control group
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by about 4-folds towards DBTRG-05MG compared to lower 
chamber without DBTRG-05MG (p<0.05) (Figure 4(D)). 
CELL MIGRATION WITH PLANT EXTRACT
Based on the anti-proliferative assay, optimum QI-100%, 
QI-70% and tamoxifen concentrations were determined 
(Table 5). These concentrations were used to treat H9-
hNSC cells prior to cell migration assay. The concentrations 
chosen were based on the optimum concentration that able 
to eradicate more than 50% of DBTRG-05MG cells but lesser 
than 50% of H9-hNSC cells. Temozolomide was excluded 
from subsequent study due to its ineffectiveness to kill 
glioma. All QI-treated H9-hNSC and Tamoxifen treated 
H9-hNSCs showed migration into the membrane of the 
insert (Figure 5(A)-5(C); black arrows), similar to the 
untreated H9-hNSCs (negative control) (Figure 5(D); black 
arrows). The migrated cells were harvested and counted 
(Figure 5(E)). Data shows that migration capacity of H9-
hNSCs treated with either QI-100%, QI-70% or tamoxifen 
were not different than the non-treated H9-hNSCs, 
indicating the treatments did not affect the migration of 
H9-hNSC cells towards DBTRG-05MG cells. This also 
indirectly illustrated the suitability of the H9-hNSC cells 
as delivery agent for QI-100%, QI-70% or tamoxifen as 
the migration of H9-hNSC cells are not affected by any 
of these compounds. After migration assay, the viability 
of DBTRG-05MG cells at lower chamber were evaluated 
using MTT assay. It was found that that DBTRG-05MG treated 
with migrated H9-hNSCs preconditioned with QI-100% 
showed significant reduction by 20% in cell viability when 
FIGURE 5. Migration of H9-hNSC treated with (A) 25 μg/mL of QI-100%, (B) 35 μg/mL of QI-70%, (C) 10 μg/mL of 
tamoxifen and (D) non-treated H9-hNSC. Migrated H9-hNSC is indicated by black arrows. Magnification: 40X. (E) 
Quantification of migrated H9-hNSC. Each point represents average ± SD of three independent experiments. There 
was no different in migration capacity among these cells, as compared to the non-treated control, indicated treatment 
with QI-100%, QI-70% and tamoxifen had no effects on H9-hNSC migration capacity
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compared to control (non-treated H9-hNSCs) (Figure 6; 
p<0.05), suggesting that the H9-hNSC not only migrate 
by itself, but it carries along the QI-100% extract which 
induced the DBTRG-05MG cell death when it reaches 
the DBTRG-05MG. However, surprisingly, DBTRG-05MG 
treated with migrated H9-hNSCs preconditioned with 
tamoxifen (positive control) did not show significant cell 
reduction after migration assay. Considering that timing 
is an important factor for drug cytotoxicity effect, thus 
we postulated the cytotoxicity of Tamoxifen was limited 
by the shorter duration set for cell migration assay as 
compared to cytotoxicity assay (12 h vs. 72 h). However, 
further detailed evaluation on the cell death mechanism 
induced by QI extracts, as well as tamoxifen, is necessary 
to confirm this.
DISCUSSION
Herbal medicines have been used for many decades and 
in fact, they are still being used in many developing 
countries as the primary source of medical treatment 
(Greenwell & Rahman 2015). Recently, variety of 
bioactive compounds in traditional herbal plants had gained 
interest among researchers and was studied extensively 
to explore their potential medicinal effects scientifically. 
This is particularly important as until today, the usage 
of traditional herb by local community is still not well 
regulated and mostly is prescribed by non-physician, 
thus, causing a lot of associated risks and side effects 
(Greenwell & Rahman 2015). Therefore, in this study, we 
opt to carefully investigate the major components in the 
QI plant and determine its cytotoxicity to human cells. We 
found that the QI plant studied in this research contains 
two major phenolic bioactive compounds which are TA 
and GA that can be extracted using soxhlet technique. 
However, an appropriate solvent must be carefully opted 
before running the soxhlet extraction because the extracted 
compound could vary depending on the type of solvent 
chosen. Methanol solvent was chose to extract phenolic 
compounds in this study because solubility of polyphenol 
is highest in methanol (Rao et al. 2013). The highest yield 
is commonly achieved by using sole methanol or their 
mixture with water. In this study, the effects of two different 
percentages of methanol (100% vs. 70%) on the extract 
yield were performed. We found that in comparison of QI 
methanol extracts, 100% methanol extract (QI-100%) had 
higher yield compared to 70% methanol extract (QI-70%). 
Furthermore, free radical scavenging activity was also 
noticed higher in QI-100% compared to QI-70% methanol 
extract, meaning QI-100% methanol extract had higher 
antioxidant activity compared to QI-70% methanol extract. 
However, in this study, there was no significant different 
between the two. In order to further validate this finding, 
we quantified the bioactive compounds extracted in both QI 
methanol extracts using standard HPLC analysis (Sasidharan 
et al. 2011). Similarly, despite the HPLC analysis showed 
that QI-100% methanol extract contained faintly higher 
percentage and concentration of TA and GA, the result 
was not significant. Taken all together, these data showed 
that extraction yield, antioxidant properties and phenolic 
compound yield from QI galls are not depending on the 
concentration of methanol solvents. 
 Nonetheless, in line with HPLC data which showed 
that both QI extracts (QI-100% and QI-70%) contained 
high amount of TA and GA, we found that these extracts 
also showed significant inhibitory effect on GBM cell line. 
The ability of QI methanol extracts to kill DBTRG-05MG 
indicated anti-proliferative property of QI towards glioma 
cells. This finding is much compatible with Hasmah et al. 
(2010) that mentioned about anti-proliferative properties of 
QI gall extracts against various cancer cells (Hasmah et al. 
2010). On the other hand, both QI extracts showed low or 
even no toxicity to human normal brain glial and stem cells, 
proving its safety for treatment. Although the mechanism 
underlying the inhibition of cancerous cell growth by QI 
extracts is still under investigation, we postulated that this 
FIGURE 6. Effects of non-treated (control) and treated (QI-100%, QI-70% and tamoxifen) H9-hNSC on DBTRG-05MG cell 
viability after 12 h migration assay. Each point represents average ± SD of three independent experiments. The viability of 
DBTRG-05MG cells were evaluated using MTT assay. DBTRG-05MG treated with migrated H9-hNSCs preconditioned with 
QI-100% showed significant reduction in cell viability, compared to control (non-treated H9-hNSCs) (p<0.05 vs. non-treated 
(control). However, there was no significant DBTRG-05MG cell reduction induced by tamoxifen-treated H9-hNSCs
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specific cytotoxicity effect could be due to the mechanism 
of the two major phenolic acids (TA and GA) found in 
QI plant. TA is a naturally occurring plant polyphenol, 
composed of a central glucose molecule derivatized at its 
hydroxyl groups with one or more galloyl residues, whilst 
GA is a trihydroxybenzoic acid which is widely distributed 
in green tea, red wine and grapes, oak bark, and other 
plants. A considerable amounts of experimental data on 
the antioxidant activity of both TA and GA with emphasis 
on structure-function antioxidant activity have been 
reported (Rao et al. 2013). The mechanism of antioxidant 
properties is mainly due to their hydrogen-donating 
and metal-chelating capacities which confer protection 
against Reactive Oxygen Species (ROS) which is elevated 
in almost all cancer types to promote many aspects of 
tumor development and progression. Therefore, reduction 
or detoxification of ROS in cancer cells by antioxidant 
compounds could help to inhibit cancer cell proliferation. 
Although extensive studies have been carried out on the 
inhibitory effect of phenolic acids against various cancers, 
to date, the IC50 for both brain cancerous cells (DBTRG-
05MG) and brain normal stem cells (H9-hNSC) and glial 
cells (SVG-p12) treated with QI-100% and QI-70% has not 
been published elsewhere. 
 Moreover, two clinically used chemotherapy drugs: 
the Temozolomide and Tamoxifen were also tested in 
this study. Temozolomide is now used worldwide to 
treat the GBM, as well as some other brain cancer types. 
In combination with radiotherapy, Temozolomide has 
become the international standard-of-care for thousands 
of people with this type of cancer (Villani et al. 2017). 
However, to our surprise, we found that the IC50 of 
Temozolomide was more than 100 µg/mL for DBTRG-
05MG, while IC50 of QI-100% and QI-70% was lower at 
23 and 34 µg/mL, respectively. This means that the potent 
of this clinical drug is less than the QI extracts, suggesting 
that the usage of this clinical drug for GBM treatment 
perhaps needs a re-evaluation and further investigation. 
Our suggestion is supported by Yoshino et al. (2010) study 
which testified that different malignant glioma cell lines 
exhibit different IC50 value for Temozolomide that ranged 
from 23.0 to 441.6 µM (Yoshino et al. 2010), showing that 
the efficiency of Temozolomide is tumor type-dependent 
and may not suitable for all types of brain cancers. On the 
other hand, the other clinical chemodrug, Tamoxifen, was 
found to be toxicity to both cancerous GBM cell line and 
normal brain NSC and glial lines at low concentration. This 
illustrated the non-specific feature of Tamoxifen inhibitory 
mechanism and its possibility to induce unwanted side 
effects to the patients. 
 Last but not least, there are many in vitro and in vivo 
studies demonstrated migration capacity of NSCs towards 
glioma as this unique feature can be useful as potential 
delivery agent of therapeutic drugs to eradicate glioma 
(Aboody et al. 2000; Heese et al. 2005). Nonetheless, 
to date, there is no published article on the migration 
of NSCs packaged with QI plant extracts towards glioma 
in vitro. In this study, we successfully demonstrated the 
migration capacity of H9-hNSCs towards DBTRG-05MG 
seeded in the lower chamber after treated with QI-100% 
and QI-70%, respectively. However, it is worth noting 
that this migration assay was performed on a Boyden 
migration chamber for 12 h only as any further migration 
duration could trigger unwanted migration by gravity 
force. Moreover, we also reported that H9-hNSCs treated 
with QI-100% successfully reduced DBTRG-05MG cell 
number in lower chamber after 12 h migration. There 
are possibilities that H9-hNSCs penetrated the Boyden 
upper chamber membrane barrier into lower chamber with 
DBTRG-05MG cells and inhibited DBTRG-05MG cell growth 
with the QI-100% extract. The migration of stem cell to 
cancer cell was mainly due to the chemotatic cytokines and 
signaling pathways (SDF-1/CXCR4 axis) involved in stem 
cell trafficking. Stromal-derived factor-1 (SDF-1) is an 
alpha-chemokine that binds to G-protein-coupled CXCR4, 
regulating the CXCR4+ stem/progenitor cell migration to 
SDF-1+ glioma tumor (Vagima et al. 2011).
CONCLUSION
Here, we successfully demonstrated that QI 100% and 
70% methanol extracts exhibited anti-proliferative 
properties against DBTRG-05MG cell line in vitro. 
Furthermore, migrated H9-hNSC cells towards DBTRG-
05MG cells in the modified Boyden chamber proved the 
unique feature of NSCs tropism to glioma. The novelty of 
this study was the evaluation of cytotoxicity effect of QI 
methanol extracts on human brain stem and cancer cells, 
as well as the migration capacity of human brain stem 
cell loaded with the optimum concentration of QI extracts 
towards human brain cancer cells in a modified Boyden 
chamber. This study showed that the NSCs were able to 
uptake and delivers QI plant extracts towards glioma and 
significantly reduced the glioma cell numbers in vitro. In 
conclusion, the use of NSC as delivery agent to deliver 
natural QI plant active compounds as anti-cancer drug for 
brain cancer chemotherapy could be possible and this has 
opened new possibilities for improvement of the quality 
of life of cancer patients. 
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